Competing interests
MH
ONCOLOGY
JSH received financial support for travel expenses by Synimmune GmbH. RFS received financial support for consulting Daiichi Sankyo, Pfizer; for speakers' Bureau by Pfizer, Daiichi Sankyo, Novartis; travel expenses by Daiichi Sankyo; research funding by PharmaMar, AstraZeneca, Pfizer, Daiichi Sankyo, Roche. MH received honoraria from Abbvie, Eurocept, Jazz Pharmaceuticals, Janssen, Novartis, Takeda; financial support for consulting or advisory role by Abbvie, Agios, BMS, Daiichi Sankyo, Glycostem, Jazz Pharmaceuticals, Kura Oncology, Novartis, Pfizer, PinotBio, Roche, Tolremo, for research funding to institution by Abbvie, Agios, Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Glycostem, Jazz Pharmaceuticals, Loxo Oncology, Novartis, Pfizer, PinotBio, Roche. FT received financial support for consulting or advisory Role by Daiichi Sankyo, Pfizer, Abbvie, Celgene, Astellas. GJ for consulting or advisory role by Synimmune, GmbH. HRS received financial support for consulting or advisory board membership by BMS, Celgene, Novartis, Pfizer, Roche, Synimmune GmbH; HRS received research funding to institution by ABL Bio, Celgene, Novartis, Synimmune GmbH. GJ, LGH and MS are shareholders of Synimmune GmbH. DE received lecture fees by Pfizer. All other authors declare no competing interests.